Igmesine inhibition of vip-induced jejunal hypersecretion in rats; Involvement of endogenous somatostatin and nervous pathways

Fargeau, H.; Rivière, Pierre; Junien, J.L.; Chovet, M.

doi:10.1016/s0016-5085(98)81490-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This activity may involve the myenteric plexus and/or intrinsic sensory nerves as the antisecretory action of other sigma ligands such as igmesine was demonstrated to be TTX sensitive in vitro 21 and in vivo. 41 Enterotoxins bind enterocyte receptors, triggering intracellular events (for example, increase in cyclic nucleotide concentration) leading to water secretion. For example, E coli-sta binds cell surface receptors and activates two membrane associated cyclic GMP dependent kinases.…”

Section: Discussionmentioning

confidence: 99%

Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

Theodorou¹

2002

Gut

View full text Add to dashboard Cite

Background and aims: Sigma ligands display antisecretory activity against various secretagogues, suggesting antidiarrhoeal properties. In this study, we evaluated: (i) the antidiarrhoeal effect of JO 2871, a high affinity sigma ligand, in three models of toxigenic diarrhoea in mice; and (ii) the site and mechanism of action of this compound. Methods: Faeces were collected after toxin or vehicle administration in male DBA2 or NMRI mice. Diarrhoea was determined by cumulative stool weight (mg) over a 120 minute period. Diarrhoea was induced by intravenous administration of Salmonella enteriditis lipopolysaccharide (LPS), or oral administration of Escherichia coli heat stable (E coli-sta) or Clostridium difficile toxins. Two sigma ligands, igmesine and JO 2871, were administered either orally or intravenously, 60 and 30 minutes before the toxins, respectively. JO 2871 was also given orally 30 minutes after E coli-sta. In addition, JO 2871 was administered intracerebroventricularly five minutes before LPS and E coli-sta. BMY 14802 (1000 µg/kg orally), a sigma receptor antagonist, or cyclosomatostatin (CSS 1 µg/kg intravenously), a somatostatin antagonist, were given five minutes prior to JO 2871 in LPS, E coli-sta, and C difficile toxin treated mice. Gastric emptying and intestinal transit were evaluated after oral JO 2871 and BMY 14802 and intravenous CSS. Results: Stool weight measured 120 minutes after administration of the toxins was significantly increased. Oral JO 2871 and igmesine dose dependently inhibited toxigenic diarrhoea in all models. ED 50 values obtained using JO 2871 (1-20 µg/kg) were more than 40 times lower than those obtained with igmesine. Oral JO 2871 given after E coli-sta also inhibited diarrhoea in a dose dependent manner (ED 50 50 µg/kg). Both sigma ligands were active by the intravenous route on LPS and E coli-sta induced stool weight increases. JO 2871 administered intracerebroventricularly failed to block this effect at any dose tested. Both BMY 14802 and CSS reversed the antidiarrhoeal effect of oral JO 2871. JO 2871, BMY 14802, and CSS did not affect transit parameters. Conclusions: JO 2871 exerts a potent oral antidiarrhoeal effect, acting peripherally through sigma sites and somatostatin release.

show abstract

Section: Discussionmentioning

confidence: 99%

Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

Theodorou¹

2002

Gut

View full text Add to dashboard Cite

show abstract

Igmesine inhibition of vip-induced jejunal hypersecretion in rats; Involvement of endogenous somatostatin and nervous pathways

Cited by 1 publication

References 0 publications

Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

Antidiarrhoeal properties of a novel sigma ligand (JO 2871) on toxigenic diarrhoea in mice: mechanisms of action

Contact Info

Product

Resources

About